A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA) (ACE-536-MDS-005) | HMA-EMA Catalogues of real-world data sources and studies